Evidence map›Paper›PMID 41114241›Full record

ReviewACS omega2025

GPR17 in Glioblastoma: Structure, Ligand Interactions, and Therapeutic Targeting.

Ramalakshmi Satyanarayana, Sree Somala Chaitanya, Iswarya Suresh Kumar, Ramesh Thiyagarajan, Sureka Chandrabose, Kasim S Abass, Saravanan Konda Mani, Anand Thirunavukarasou, Meenakshisundaram Kandhavelu

Abstract readReview
In one paragraph

Review in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ramalakshmi SatyanarayanaFaculty of Clinical Research, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu 600116, India.
Sree Somala ChaitanyaB Aatral Biosciences Private Limited, Bengaluru, Karnataka 560091, India.
Iswarya Suresh KumarB Aatral Biosciences Private Limited, Bengaluru, Karnataka 560091, India.ORCID https://orcid.org/0009-0007-0505-3848
Ramesh ThiyagarajanDepartment of Basic Medical Sciences, College of Medicine, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia.
Sureka ChandraboseDepartment of Basic Medical Sciences, College of Medicine, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia.
Kasim S AbassDepartment of Physiology, Biochemistry, and Pharmacology, College of Veterinary Medicine, University of Kirkuk, Kirkuk 36003, Iraq.
Saravanan Konda ManiB Aatral Biosciences Private Limited, Bengaluru, Karnataka 560091, India.ORCID https://orcid.org/0000-0002-5541-234X
Anand ThirunavukarasouFaculty of Clinical Research, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu 600116, India.
Meenakshisundaram KandhaveluMolecular Signaling Group, Faculty of Medicine and Health Technology, Tampere University, Tampere 33101, Finland.ORCID https://orcid.org/0000-0002-4986-055X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

G protein-coupled receptor 17 (GPR17) is a crucial protein encoded by the GPR17 gene, which belongs to the G protein-coupled receptor (GPCR) family. It serves a pivotal function in cellular responses to various stimuli. GPR17 is found in various organs, including the brain, spinal cord, kidneys, liver, and immune cells. It is especially prevalent in oligodendrocytes, underscoring its significance in myelination. GPR17 is involved in myelination, inflammation, and neuroprotection. Recent studies highlight the therapeutic potential of targeting GPR17 in glioblastoma, a highly aggressive brain cancer, as it is overexpressed in tumor tissues and plays a critical role in tumor progression and invasion. Understanding the structure of GPR17 and its interactions with ligands and functional signaling pathways is crucial for developing targeted therapeutics for conditions involving myelin degradation, neuroinflammation, and immune dysregulation. To guide this exploration, this review is organized into distinct sections covering the sequence and structural features of GPR17, its natural and synthetic ligands, its role in glioblastoma progression, its associated signaling pathways, and the potential of using GPR17 as a therapeutic target. Each section in the review consolidates current findings to offer an integrated view of GPR17 biology and its translational relevance in oncology.

Identifiers

PMID41114241
PMCPMC12529388

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.